文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.

作者信息

Weidenbacher Payton A-B, Sanyal Mrinmoy, Friedland Natalia, Tang Shaogeng, Arunachalam Prabhu S, Hu Mengyun, Kumru Ozan S, Morris Mary Kate, Fontenot Jane, Shirreff Lisa, Do Jonathan, Cheng Ya-Chen, Vasudevan Gayathri, Feinberg Mark B, Villinger Francois J, Hanson Carl, Joshi Sangeeta B, Volkin David B, Pulendran Bali, Kim Peter S

机构信息

Sarafan ChEM-H, Stanford University, Stanford, CA, USA.

Department of Chemistry, Stanford University, Stanford, CA, USA.

出版信息

bioRxiv. 2022 Dec 26:2022.12.25.521784. doi: 10.1101/2022.12.25.521784.

DOI:10.1101/2022.12.25.521784
PMID:36597527
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9810210/
Abstract

While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. Following a booster ∼one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. DCFHP-alum has potential as a once-yearly booster vaccine, and as a primary vaccine for pediatric use including in infants.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/141745d615af/nihpp-2022.12.25.521784v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/284dbc246451/nihpp-2022.12.25.521784v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/0734eca2b4eb/nihpp-2022.12.25.521784v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/cde302a3e016/nihpp-2022.12.25.521784v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/e4c987839bfa/nihpp-2022.12.25.521784v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/2811200c772f/nihpp-2022.12.25.521784v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/141745d615af/nihpp-2022.12.25.521784v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/284dbc246451/nihpp-2022.12.25.521784v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/0734eca2b4eb/nihpp-2022.12.25.521784v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/cde302a3e016/nihpp-2022.12.25.521784v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/e4c987839bfa/nihpp-2022.12.25.521784v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/2811200c772f/nihpp-2022.12.25.521784v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08fe/9810210/141745d615af/nihpp-2022.12.25.521784v1-f0006.jpg

相似文献

[1]
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.

bioRxiv. 2022-12-26

[2]
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.

Nat Commun. 2023-4-17

[3]
Decreased efficacy of a COVID-19 vaccine due to mutations present in early SARS-CoV-2 variants of concern.

bioRxiv. 2023-6-29

[4]
Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.

Vaccine. 2023-10-20

[5]
Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates.

Nat Commun. 2023-3-10

[6]
A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2.

Vaccines (Basel). 2023-10-1

[7]
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.

J Infect. 2023-9

[8]
Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates.

bioRxiv. 2021-3-25

[9]
Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice.

Viral Immunol. 2023-10

[10]
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.

Elife. 2022-8-25

引用本文的文献

[1]
Defining and using immune archetypes to classify and treat cancer.

Nat Rev Cancer. 2023-7

本文引用的文献

[1]
Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.

Vaccine. 2023-10-20

[2]
Monoclonal antibody levels and protection from COVID-19.

Nat Commun. 2023-7-28

[3]
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.

Sci Transl Med. 2023-3-22

[4]
A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines.

N Engl J Med. 2022-12-15

[5]
Urgent Need for Next-Generation COVID-19 Vaccines.

JAMA. 2023-1-3

[6]
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.

Cell. 2022-7-7

[7]
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.

Lancet Infect Dis. 2022-9

[8]
Correlates of protection against SARS-CoV-2 infection and COVID-19 disease.

Immunol Rev. 2022-9

[9]
Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity.

Cell. 2022-4-28

[10]
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.

Cell. 2022-3-17

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索